The treatment of ovarian cancer by a multimodality approach: Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation

A. Goldhirsch, R. Greiner, E. Dreher, G. Locher, B. W. Davis, J. P. Reinhard, R. Joss, K. W. Brunner

Research output: Contribution to journalArticlepeer-review

Abstract

Seventy-six evaluable patients with ovarian carcinoma stages FIGO IIb, IIe, III, and IV, either received cis-platin (P) (80mg/m2 iv. day 1), melphalan (PAM) (12mg/m2 i.v. day 2) and hexamethylmelamine (IIEXAPAMP) (135mg/m2 orally days 8 to 21) or the same dose of cis-platin and melphalan but no hexamethylmelamine (PAMP) every four weeks. In 24 patients (32%) a surgically ascertained CR was achieved. 16 of these received follow-up radiation treatment to the whole abdomen. At present 19 patients are without relapse (average time 24 months). The trial has not been concluded. Particularly no predictions can be made on the value of follow-up radiation therapy in obtaining long-term remission rates.

Original languageEnglish
Pages (from-to)383-387
Number of pages5
JournalOncology Research and Treatment
Volume8
Issue number6
DOIs
Publication statusPublished - 1985

Keywords

  • Chemotherapy
  • Ovarian cancer
  • RadiationReferences

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'The treatment of ovarian cancer by a multimodality approach: Remission induction with chemotherapy - hexa p amp and p amp regimens - followed by whole-abdominal radiation'. Together they form a unique fingerprint.

Cite this